Longeveron (LGVN) Cash & Equivalents (2021 - 2026)
Longeveron's (LGVN) quarterly Cash & Equivalents came in at $15.8 million in Q1 2026, up 9.99% year-on-year from $14.3 million in Q1 2025, and up 238.08% quarter-over-quarter from $4.7 million in Q4 2025.
Longeveron (LGVN) Cash & Equivalents (2021 - 2026) Analysis & Trends
Longeveron's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 9.99% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 9.99% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, down 75.76% from the prior year.
- Cash & Equivalents grew to $15.8 million in Q1 2026 per LGVN's latest filing, from $4.7 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $22.8 million in Q3 2024 and bottomed at $1.9 million in Q1 2023.
- The 5-year median for Cash & Equivalents is $9.8 million (2025), against an average of $9.5 million.
- Across the five-year window, Cash & Equivalents jumped 1058.01% in 2024 and tumbled 75.76% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $10.5 million in 2022, then tumbled by 52.88% to $4.9 million in 2023, then soared by 288.6% to $19.2 million in 2024, then tumbled by 75.76% to $4.7 million in 2025, then soared by 238.08% to $15.8 million in 2026.
- Per Business Quant, the three latest LGVN Cash & Equivalents figures stand at $15.8 million (Q1 2026), $4.7 million (Q4 2025), and $9.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Longeveron | 15.28 Bn | 15.26 Bn | 264,000.00 | 15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.76 Mn |
| Dec 31, 2025 | 4.66 Mn |
| Sep 30, 2025 | 9.24 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 14.33 Mn |
| Dec 31, 2024 | 19.23 Mn |
| Sep 30, 2024 | 22.78 Mn |
| Jun 30, 2024 | 12.40 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 2.75 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 10.50 Mn |
| Dec 31, 2021 | 25.66 Mn |